In the clinic, once metastatic breast cancers have developed resistance to endocrine therapy, alone or in combination with a CDK4/6 inhibitor (first and second-line), patients are switched to chemotherapy and the tumors are normally not re-challenged with further endocrine treatments based on the assumption that estrogen signaling has ceased to play a role in cancer survival. The gene discussed is CDK4; the disease is breast carcinoma.